[PDF][PDF] Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an …
A Attarbaschi, G Mann… - Journal of Clinical …, 2008 - researchgate.net
A Attarbaschi, G Mann, R Panzer-Grümayer, S Röttgers, M Steiner, M König, E Csinady…
Journal of Clinical Oncology, 2008•researchgate.netMinimal Residual Disease Values Discriminate Between Low and High Relapse Risk in
Children With B-Cell Precursor Acute Lymphobla Page 1 Minimal Residual Disease Values
Discriminate Between Low and High Relapse Risk in Children With B-Cell Precursor Acute
Lymphoblastic Leukemia and an Intrachromosomal Amplification of Chromosome 21: The
Austrian and German Acute Lymphoblastic Leukemia Berlin-FrankfurtMunster (ALL-BFM) Trials
Andishe Attarbaschi, Georg Mann, Renate Panzer-Grümayer, Silja Röttgers, Manuel Steiner …
Children With B-Cell Precursor Acute Lymphobla Page 1 Minimal Residual Disease Values
Discriminate Between Low and High Relapse Risk in Children With B-Cell Precursor Acute
Lymphoblastic Leukemia and an Intrachromosomal Amplification of Chromosome 21: The
Austrian and German Acute Lymphoblastic Leukemia Berlin-FrankfurtMunster (ALL-BFM) Trials
Andishe Attarbaschi, Georg Mann, Renate Panzer-Grümayer, Silja Röttgers, Manuel Steiner …
Conclusion
The overall and early relapse rates in the BFM study were lower than that in a previous United Kingdom Medical Research Council/Childhood Leukemia Working Party study (38% v 61% and 27% v 47%, respectively), which might result from more intensive induction and early reintensification therapy in the ALL-BFM protocols. MRD values were the only reliable parameter to discriminate between a low and high risk of relapse (P. 02).
researchgate.net